Comparative analysis of immune-associated genes in COVID-19, cardiomyopathy and venous thromboembolism
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
As of 28 August 2020, there have been 5.88 million Coronavirus Disease 2019 (COVID19) cases and 181,000 COVID-19 related deaths in the United States alone. Given the lack of an effective pharmaceutical treatment for COVID-19, the high contagiousness of the disease and its varied clinical outcomes, identifying patients at risk of progressing to severe disease is crucial for the allocation of valuable healthcare resources during this pandemic. Current research has shown that there is a higher prevalence of cardiovascular comorbidities amongst patients with severe COVID-19 or COVID-19-related deaths, but the link between cardiovascular disease and poorer prognosis is poorly understood. We believe that pre-existing immune dysregulation that accompanies cardiovascular disease predisposes patients to a harmful inflammatory immune response, leading to their higher risk of severe disease. Thus, in this project, we aim to characterize immune dysregulation in patients with cardiomyopathy, venous thromboembolism and COVID-19 patients by looking at immune-associated gene dysregulation, immune infiltration and dysregulated immunological pathways and gene signatures.
Article activity feed
-
SciScore for 10.1101/2020.08.28.20184234: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:However, we recognize our study has several limitations. We had limited COVID19 platelet data, specifically normal patients. Thus, our differential expression analysis may have been impacted, and the statistical power of our analysis is reduced. However, the direction of dysregulation of many of the genes we identified were consistent …
SciScore for 10.1101/2020.08.28.20184234: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:However, we recognize our study has several limitations. We had limited COVID19 platelet data, specifically normal patients. Thus, our differential expression analysis may have been impacted, and the statistical power of our analysis is reduced. However, the direction of dysregulation of many of the genes we identified were consistent with existing literature. Additionally, we used platelet data, instead of blood samples. In order to validate our results, in vitro and in vivo experiments can be done in the future. Despite these limitations, we believe our study advances our understanding of the relationship between cardiovascular disease and COVID-19.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
